what is the better biomarkers for acute tbi

GPT-5.4

Vote: gfap

GFAP is generally the better biomarker for acute TBI. Its main advantage is timing. GFAP rises rapidly after injury, often within hours, which makes it more useful in the acute emergency setting when early diagnosis and triage matter most. It is also more established clinically for acute head injury. GFAP has strong evidence for detecting intracranial injury and has been incorporated into FDA-cleared blood test strategies for mild TBI assessment. By contrast, NfL is valuable but tends to peak later and is often more informative for injury burden, prognosis, or subacute/chronic axonal damage rather than the earliest acute decision-making. So if the question is specifically the better biomarker for acute TBI, GFAP is the stronger choice.

Claude Opus 4.6

Vote: gfap

GFAP (Glial Fibrillary Acidic Protein) is the better biomarker for **acute** TBI for several compelling reasons: **Rapid elevation after injury:** GFAP rises within hours of a traumatic brain injury, typically peaking within 20-24 hours post-injury. This rapid kinetic profile makes it ideal for acute detection and triage in emergency settings. In contrast, NfL (Neurofilament Light chain) rises more slowly, often peaking days to weeks after injury, making it better suited for subacute or chronic phases. **FDA-approved diagnostic use:** GFAP, in combination with UCH-L1, is part of the FDA-cleared Banyan BTI (Brain Trauma Indicator) test — the first blood test approved to evaluate mild TBI and help determine the need for CT scanning. This regulatory milestone underscores GFAP's validated clinical utility in the acute setting. **Reflects acute glial damage:** GFAP is released from damaged astrocytes, which are among the first cells affected in acute brain trauma. This makes it a direct marker of the acute pathological process. NfL reflects axonal damage, which can be a more delayed and progressive process. **Strong evidence for acute CT-positive lesion detection:** Multiple large studies (including the TRACK-TBI study) have demonstrated that GFAP has excellent sensitivity and specificity for detecting intracranial lesions on CT in the acute phase, often outperforming clinical decision rules alone. **NfL's strength is elsewhere:** NfL is arguably superior for monitoring long-term outcomes, chronic neurodegeneration, and repeated head injuries over time. But for the specific question of *acute* TBI biomarking, GFAP is the established and evidence-supported choice.

Gemini 3.1 Pro

Vote: gfap

GFAP (Glial fibrillary acidic protein) is widely considered the superior biomarker for acute Traumatic Brain Injury (TBI). It is released rapidly into the bloodstream following brain injury, with levels peaking within the first 24 hours. This immediate kinetic profile makes it highly sensitive and actionable for acute diagnostics. In fact, GFAP (in combination with UCH-L1) has received FDA clearance specifically for evaluating mild TBI in the acute setting (within 12 hours of injury) to help rule out the need for a head CT scan. It is highly specific to glial cell damage and effectively flags acute intracranial lesions. Conversely, NfL (Neurofilament light chain) is an excellent biomarker for axonal damage, but its levels take significantly longer to peak in the blood (typically days to weeks post-injury). Because of this delayed rise, NfL is much better suited for evaluating subacute to chronic TBI and predicting long-term neurodegenerative outcomes, whereas GFAP is the clinical standard for the immediate, acute phase.

Final Summary

The AI Roundtable reached an immediate and unanimous consensus, declaring GFAP the superior biomarker for acute TBI due to its rapid kinetic profile and established clinical utility. While Claude Opus 4.6 and Gemini 3.1 Pro acknowledged NfL's value in long-term prognosis, they joined GPT-5.4 in emphasizing that GFAP’s ability to peak within hours makes it the only viable choice for emergency triage and ruling out the need for CT scans.

All 3 models agreed on "gfap" after discussion

Strongest Arguments

• gfap: GFAP's rapid elevation within hours of injury and its inclusion in the FDA-cleared Banyan BTI test make it the validated clinical standard for acute intracranial lesion detection, whereas NfL levels peak too late for emergency diagnostics.